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1015-9584/Copyright ª 2014, Asian SuSummary Aim: The aim of this study was to analyze our experience with rectal cancer
patients who underwent surgical excision at our institution.
Methods: Data on 112 rectal cancer patients who underwent surgical resection with total
mesorectal excision, from January 2005 to December 2008, were evaluated retrospectively.
Results: Weachieved an initial complete remission rate of 74.1%. Overall, 92.8% of patients had a
complete total mesorectal excision. The overall survival analysis for all patients showed a 1-year
survival rate of 98%, a 3-year survival rate of 82%, and a 5-year survival rate of 70%. We report a
41.9% rate of postoperative complications. The 1-, 3-, and 5-year survival rates for females were
100%, 90%, and 72%, respectively and for males, they were 90%, 80%, and 68%, respectively.
Differences in overall survival by sex were not statistically significant (p > 0.05). Those patients
who were treated with only surgery had the best outcomes with survival being worse in those
treated with surgery and adjuvant therapy. Neoadjuvant treatment followed by surgery led to
better results.
Conclusion: We conclude that we have been successful in achieving high rates of curative resec-
tion, complete remission, and overall survival. Neoadjuvant and adjuvant chemotherapy signifi-
cantly impact rates of remission.
Copyrightª2014,AsianSurgicalAssociation. PublishedbyElsevierTaiwanLLC.All rights reserved.declare no competing interests.
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14 A.I. Malik et al.1. IntroductionAlthough rectal cancer is often seen as part of the much
broader entity of colorectal cancer, the pathological course
and treatment regimens of cancers of the rectum and the
colon differ considerably,1 and outcomes of treatment are
also different. Colorectal cancer is one of the 10 most
common malignancies worldwide, with high rates being
reported from North America, Australia, New Zealand,
Western Europe, and Japan. Asian and African countries are
generally considered areas of low incidence. In 1995, can-
cers of the rectum and colon taken together were the
seventh most common cancer in males and the ninth most
common in females in Pakistan.2 Gradually increasing rates
are now being reported from South Asian as well as Euro-
pean countries.3e5 Bhurgri et al,3 reporting on results from
Pakistan’s only population-based cancer registry, reported
the crude incidence rate of rectal cancer increasing from
1.7/100,000 in 1995e1997 to 2.3/100,000 in 1998e2002 in
Karachi, Pakistan. As well as increasing incidence, younger
age at diagnosis is also now being widely reported.3,4,6
The cornerstone of management of rectal cancer pa-
tients is optimal surgical excision. Total mesorectal excision
(TME) guarantees complete excision of the lymphatics
around the rectum, contained within the mesorectum, and
ensures adequate resection margins and circumferential
tumor clearance.7 As well as improved techniques of sur-
gical excision, the past two decades have seen major ad-
vances in the application of neoadjuvant and adjuvant
treatment, using chemotherapy and radiation therapy.
Today, these are integral parts of the treatment regimens
for these patients.6 Neoadjuvant chemoradiation has been
shown to be beneficial in leading to a reduction in local
recurrence in rectal cancer.8 Neoadjuvant therapy has also
been shown to result in complete pathological response in
stage IV rectal cancer.9 According to Naiken et al,9 10e20%
of patients achieve complete pathological response after
chemoradiation. Primary surgical excision is currently rec-
ommended for stage I patients, whereas neoadjuvant
chemotherapy and radiation followed by surgery, with or
without adjuvant treatment, is considered appropriate for
stages II and III rectal cancer.10
Radical surgery in these patients has led to high rates of
morbidity associated with the surgical procedure itself as
well as with prolonged hospital stay. Surgery also requires
either a defunctioning or permanent colostomy, which
many patients have difficulty accepting and becoming
accustomed to, leading to a reduced quality of life.7
The Shaukat Khanum Memorial Cancer Hospital and
Research Center is a tertiary-level, dedicated cancer hos-
pital located in Lahore, Pakistan, a city with a population of
16 million.2 The aim of this study was to analyze the out-
comes of patients with rectal cancerwho underwent surgical
excision at our institution, and to review their postoperative
morbidity, curative resection rates, recurrence rates, and
overall survival.
2. Patients and methods
As a follow-up of a previous publication from our institution
that focused on colonic as well as rectal cancer patients,2we retrieved retrospectively data on rectal cancer pa-
tients treated at our institution from January 2005 to
December 2008. A total of 336 rectal malignancies were
registered during this 4-year period. Of this total, 112 pa-
tients, all histologically confirmed, who underwent surgery
[abdominoperineal resection (APR) and low anterior
resection (LAR)], along with total mesorectal resection, at
the hospital were selected for complete review in this
study. Rectal cancer was defined as a tumor occurring
above the anal canal and within 15 cm of the anal verge.
Patients were staged according to the American Joint
Committee for Cancer (AJCC) staging of cancers for the
colon and rectum.11 To facilitate the review, stages I and II
were combined into “Early Stage Cancer” and stages III and
IV were grouped into “Late Stage Cancer.” All patients with
rectal cancer were staged in a uniform manner with
contrast-enhanced computerized tomographic scans of the
chest and abdomen, and contrast-enhanced magnetic
resonance scan of the pelvis. Imaging was usually done at
our center, and any studies performed elsewhere were
reviewed by radiologists at our institution for adequacy,
prior to rereporting. Where imaging studies performed
elsewhere were felt to be inadequate, these were repeated
at our institution. Only those carcinoembryonic antigen
(CEA) levels done at our center were included. Prior to
surgery, all rectal cancer patients treated at our institution
are usually given neoadjuvant chemoradiation. This con-
sists of induction chemotherapy with CapOx regimen (oral
capecitabine 1000 mg/m2, twice a day, D1e14, and intra-
venous oxaliplatin 130 mg/m2, D1) given three times weekly
for four cycles. This is followed by pelvic radiation to a dose
of 50.4 Gy in 28 fractions with concurrent oral capecitabine
825 mg/m2, twice a day throughout radiation. Radiation is
usually computerized tomography-planned with target
volume encompassing the primary tumor and locoregional
lymph nodes. Overall survival interval was defined as date
of diagnosis to date of death. Disease-free survival (DFS)
was taken as the period from the date of surgery/end of
treatment to the date of relapse or death. Patients were
deemed as lost to follow-up if they had missed their last
scheduled appointment and a period of at least 3 months
had lapsed since.
Disease response was defined using the World Health
Organization or Response Evaluation Criteria in Solid Tumors
criteria.12 Complete response (CR) was defined as disap-
pearance of all the target lesions confirmed on imaging 4e6
weeks after treatment. Partial response was defined as at
least 30% reduction in the sum of the diameters of the target
lesions confirmed at 4e6 weeks after treatment. Progressive
disease (PD) was taken as an increase of at least 20% in the
diameters of the target lesions or appearance of a new
lesion. Stable disease was specified as neither PD nor partial
remission. Remission was defined as persistent complete
response for at least 1 year. Patients whowere lost to follow-
up were censored during survival analysis.
File review was completed in April 2012. Attempts were
made to contact telephonically all patients who had been
lost to follow-up.
The variables that were included in the analysis were
age, sex, body mass index, disease stage, family history,
histology, CEA levels, treatment modality, disease response
after treatment, perioperative blood transfusion,
Table 1 Demographics and clinical characteristics.
Frequency %
Presenting symptoms
Rectal bleeding 13 11.6







Outcomes of rectal cancer patients in Pakistan 15preoperative hemoglobin levels, and postoperative compli-
cations. We also looked at follow-up times, DFS, and overall
survival. Postoperative complications were cross-tabulated
with both body mass index (BMI) and hemoglobin level.
The survival distributions were evaluated by means of
the KaplaneMeier survival analysis. The distributions were
compared using the log-rank Chi-square test. All tests were
considered statistically significant at an < level of 0.05. A
PubMed literature search was carried out to review similar
data available for outcomes of surgically treated rectal
cancer patients.Early stage
Stage I 3 2.7
Stage II 17 15.3
Total 20 18
Late stage
Stage III 91 81.2





Squamous cell carcinoma 1 0.89
Carcinoma NOS 4 3.57
Total 112 100
ABH Z altered bowel habits; NOS Z not otherwise specified.3. Results
Of the 112 patients selected for this study, 69 (61.6%) were
males and 43 (38.4%) were females, with a male/female
ratio of 1.6:1. The mean age at presentation was 43.6
(range 16e79) years.
Rectal bleeding was the only presenting complaint in 13
(11.6%) patients. The most common combination of symp-
toms was altered bowel habit and rectal bleeding, which
was seen in 33 (29.4%) of the patients. Twenty-three
(20.5%) patients had a combination of rectal bleeding,
weight loss, and pain, and 43 (38.3%) patients had a variety
of miscellaneous symptoms including loss of appetite,
abdominal pain, nausea and vomiting, and general malaise.
Seven (6.2%) patients had a positive family history of
colorectal cancer in a first-degree relative. Eight (7.1%)
patients had a history of cancers other than colorectal
cancer in a first-degree relative. Ninety-seven (86.6%) pa-
tients had no family history of cancer.
The most common stage at presentation was stage III, as
shown in Table 1.
A total of 107 (95.5%) patients had adenocarcinoma, one
(0.89%) patient had squamous cell carcinoma, and four
(3.57%) patients had carcinoma not otherwise specified.
Sixty-six (58.9%) patients had moderately differentiated
carcinoma, whereas in 19 (16.9%) patients the histology
grade could not be assessed. The rest had poorly differen-
tiated (14, 12.5%), well-differentiated (12, 10.7%), and
undifferentiated (1, 0.89%) tumors.
The majority of our patients (64, 57.1%) had normal
(<2.5 ng/ml) CEA levels. Thirty-eight (33.9%) patients had
high levels (>2.5 ng/ml), whereas in 10 (8.9%) patients, the
initial CEA levels were not available for review. Of the 38
patients with elevated CEA levels, the majority had stage III
disease (32, 84.2%), with six (15.7%) presenting with early
stage (stages I and II) disease.
Sixty (57.1%) patients underwent APR, whereas 48
(42.8%) had LAR. Of the 64 APR procedures performed, 28
(43.7%) were carried out using a laparoscopic approach.
One hundred and four (92.8%) of the TME procedures
were complete resections. Only eight (7.1%) specimens
showed an incomplete mesorectum on examination after
resection.
R0 resection was achieved in 85 (75.9%) of 112 patients,
whereas 27 (24.1%) patients had positive margins on ex-
amination of resected specimens. Of these, 13 (48.1%) were
R1 resections and 14 (51.8%) were R2 resections. Eighteen
(66.6%) of the 27 patients with positive margins eventually
relapsed.A total of 104 patients underwent chemotherapy (neo-
adjuvant, adjuvant, or both). The most common chemo-
therapeutic regimen used was capecitabine with oxaliplatin
(CapOx) in 53 (50.9%) patients. 5-Flurouracil with folinic
acid was used in 21 (20.2%) patients. Chemotherapy had to
be delayed, stopped, or the dose reduced in 26 (25%) of
these patients, because of either toxicity or patient intol-
erance. Five of these 26 patients subsequently had positive
surgical margins and 10 had relapse of disease.
The most commonly used treatment regimen (50, 44.6%)
was neoadjuvant chemotherapy and radiation, followed by
surgical resection, then by adjuvant therapy. Eight patients
were selected to undergo surgery only. These included five
patients who had early-stage disease and three patients
who had late stage disease.
Eighty-three (74.1%) patients achieved complete remis-
sion. Of these, 38 (45.7%) were treated with neoadjuvant
therapy, surgery, and then adjuvant therapy, whereas 28
(33.7%) patients received neoadjuvant therapy followed by
surgery (Table 2). Comparing CR rates for the two types of
surgical procedures performed revealed that of the pa-
tients who underwent LAR, 68% achieved CR, compared to
46.8% in those undergoing APR.
Postoperative complications were classified according to
the ClavieneDindo classification.13 We experienced an
overall complication rate of 41.9% (Table 3). The majority of
the complications encounteredwere of grade 3a (19, 40.4%).
Of these, obstructive uropathy was the most common (15,
78.9%). Sixteen (34%) patients had grade 2 complications,
including wound infections (14, 87.5%). Twenty-four (51%) of
all complications were seen in patients with BMIs in the
normal range (18.5e25). Only nine (19%) complications
occurred in patients with low BMIs (<18.5; Table 4). There
was no statistically significant association between
Table 2 Disease response after treatment by treatment
group.
Treatment group Number Disease response
after treatment
N/A PR PD CR SD
Neoadjuvantesurgery 40 2 3 6 28 1
Surgery 8 1 6 1
Surgeryeadjuvant 14 1 1 11 1
Neoadjuvantesurgerye
adjuvant
50 3 6 2 38 1
Total 112 6 9 10 83 4
CR Z complete response; N/A Z not applicable;
PD Z progressive disease; PR Z partial remission; SD Z stable
disease.
Table 4 Postoperative complications, body mass index





Low (<18.5) 9 19.1
Normal (18.5e25) 24 51
High (>25) 14 29.7
Total 47 100
Hemoglobin
Low (<12) 24 51
Normal (12e17) 23 48.9
High (>17) 0 0
Total 47 100
16 A.I. Malik et al.BMI values and the presence or absence of postoperative
complications (p Z 0.65). Nor was there any statistically
significant association found between preoperative hemo-
globin categories (low and normal) and the presence or
absence of postoperative complications (pZ 0.46; Table 4).
Forty-four (39.2%) patients received perioperative
blood transfusions. Perioperative transfusion was defined as
a blood transfusion occurring within 7 days prior to,
during, or up to 7 days after surgery. Fourteen (31.8%) of
the 44 patients who received perioperative blood trans-
fusions also suffered from postoperative complications. We
were not able to demonstrate a clinical association be-
tween perioperative blood transfusions and postoperative
complications.
On the last review (disease status at last visit), 60
(53.5%) patients were in CR, whereas 21 patients had
relapsed and two had died. Of the patients who achieved
partial remission, only two remained in partial remission
and eight patients experienced PD, leading to a total of 17
patients with PD. Four patients maintained stable disease,
whereas disease status for six could not be determined.
Overall, 36 of 112 (32.1 %) patients had been lost to
follow-up, whereas 72 (64.2%) were under regular review.
Efforts were made, for the purpose of this review, toTable 3 Postoperative complications.
ClavieneDindo grades Frequency %
Grade 1 7 14.89
Fecal incontinence 7 100
Grade 2 16 34
Wound infections 14 87.5
Pneumonia 1 6.25
Obstructive uropathy 1 6.25
Grade 3a 19 40.4
Obstructive uropathy 15 78.9
Urethral strictures 4 21
Grade 3b 5 10.6
Anastomotic leak 3 60
Anastomotic stricture 1 20
Obstructive uropathy 1 20
Total 47 100
Overall rate 47/112 41.9contact all patients who had been lost to follow-up to
determine patient status. Of these 112 patients, 64 (57.1%)
were still alive, 22 (19.6%) had died, and current status
could not be determined for 26 (23.2%).
Overall survival was defined as the time interval be-
tween the dates of diagnosis and death. Death was taken as
the endpoint of interest. Survival analysis was carried out
using the KaplaneMeier method (Table 5). The overall
survival analysis for all patients showed a 1-year survival
rate of 98%, a 3-year survival rate of 82%, and a 5-year
survival rate of 70% (Fig. 1).
Overall survival was also analyzed by sex (Fig. 2). The 1-,
3-, and 5-year survival rates for females were 100%, 90%,
and 72%, respectively. For men, they were 90%, 80%, and
68%, respectively. The difference was not found to be
statistically significant (p Z 0.356).
DFS was computed as the time interval between treat-
ment and relapse, or between treatment and death. The
average DFS for the entire group (nZ 83) was 40.5 months.
The longest mean DFS of 49.3 months was achieved by the
“surgery only” group, followed closely by the “neoadjuvant
therapyesurgery” group at 49.2 months.
The median survival times could not be calculated for
overall survival as survival did not drop to 50%.
Our 1-, 3-, and 5-year DFS rates for late stage cancer
were 92%, 70%, and 42%, respectively. For early stage
cancer, 1-, 3-, and 5-year DFS rates were 92%, 78%, and
78%, respectively. There were no statistically significant
differences found (p Z 0.469; Fig. 3).
Analyzing data by treatment modality and late stage
disease, we found statistically significant differences be-
tween outcomes related to surgery versus surger-
yeadjuvant (p Z 0.015), surgeryeadjuvant versus
neoadjuvantesurgery (p Z 0.015), and surgeryeadjuvant
versus neoadjuvantesurgeryeadjuvant (p Z 0.039; Fig. 4).
No such differences were found in the early stage group
when stratified by treatment modality (Fig. 5).
DFS for the “surgery only” group was 100% at 1-, 3-, and 5-
years. The “surgeryeadjuvant” group showed 90% survival at
1 year followed by 36% at 3 years. The patients in this group
did not survive until 5 years. For the “neoadjuvantesurgery”
group, survival was 86% at 1 year and 86% at 3 years and 5
years. The “neoadjuvantesurgeryeadjuvant” group showed
88% and 76% for 1 year and 3 years, respectively. None of the
patients in this group survived for 5 years.
Table 5 Data for KaplaneMeier analysis.
Overall survival Total Number of events Censored
N %
Overall 112 22 90 80
By sex
Female 43 6 37 86
Male 69 16 53 76
Disease-free survival
By sex






Early 17 3 14 82
Late 66 20 46 69
By treatment modality
Surgery 6 0 6 100
Neoadjuvant þ surgery 28 4 24 86
Neoadjuvant þ surgery þ adjuvant 38 12 26 68
Surgery þ adjuvant 11 7 4 36
Disease-free survival by stage and treatment modality
Early stage:
Surgery 3 0 3 100
Neoadjuvant þ surgery 8 1 7 88
Neoadjuvant þ surgery þ adjuvant 5 1 4 80





Surgery 3 0 3 100
Neoadjuvant þ surgery 20 3 17 85
Neoadjuvant þ surgery þ adjuvant 33 11 22 67
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significant difference (p Z 0.867).
DFS was also analyzed by stage and treatment modality.
In late stage disease, there is a statistically significant
difference when comparing the “neoadjuvantesurgery”
group with the “surgeryeadjuvant group” (p Z 0.03).
There is no other statistically significant difference when
comparing various subgroups with one another, either in
early or late stage disease.4. Discussion
Our data demonstrate rates of rectal cancer in men and
women that are consistent with previous reports from the
region. Our male/female ratio was 1.6:1 compared to the
2:1 reported by Bhurgri et al.3 However, similar sex distri-
bution is not seen with reports from other parts of the
world where women had slightly higher rates of rectal
cancer, especially locally advanced rectal cancer.14 The
higher incidence in men seen in our study may be because
we see patients from all over Pakistan as well asneighboring Afghanistan. Women may not always be able to
travel as freely as men, and in some rural areas, their
health issues may be minimized or ignored.
As with other studies, we also found rectal bleeding and
altered bowel habit to be the most common combination of
presenting symptoms in patients with rectal cancer.15
Overall, 81.2% of our patients presented with AJCC stage
III. Andreoni et al1 in Italy saw UICC (Union for International
Cancer Control) stage III, which has the same stage defini-
tions as the AJCC, as the most common stage at presenta-
tion in their rectal cancer patients. This indicates a global
trend toward stage III cancers being the most common
stage at presentation. Innos et al,10 however, found slightly
higher rates of stage IV cancer (29.7%) compared to stage III
(22%) in Estonia.
Of the two different surgical procedures, LAR was seen
to be the more successful one in achieving complete
remission despite the fact that stage distribution was
similar between the two groups in our cohort. Our results
show an initial complete remission rate of 74.1%.
Our rate of R0 resections (75.9%) was slightly lower than
that reported by Andreoni et al1 (84.7%). We had a high rate
Figure 1 KaplaneMeier analysis on overall survival. Figure 3 KaplaneMeier analysis on disease-free survival by
stage.
18 A.I. Malik et al.(92.8%) of complete TME. However, a comparative analysis
could not be performed, as rates of TME have not been
reported in other recently conducted studies. TME has been
seen to be associated with good outcomes, and where TME
was not performed or was incomplete, lower survival rates
have been seen.4,6,10
Of the 83 patients who had a complete response to
treatment, 21 subsequently relapsed. A case note review
showed this to be because of positive surgical margins,Figure 2 KaplaneMeier analysis on overall survival by sex.interrupted or reduced chemotherapy and/or radiation, or
advanced cancer stage at diagnosis. Most relapses were
seen in stage III, but this may simply be because the ma-
jority of our patients presented with stage III tumors.
The probability of survival for those who underwent
surgery only was 100% at 1 year, 3 years, and 5 years after
treatment. This is likely to be because these patientsFigure 4 KaplaneMeier analysis on disease-free survival by
treatment (late stage).
Figure 5 KaplaneMeier analysis on disease-free survival by
treatment (early stage).
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longer DFS. The group treated with neoadjuvant therapy
followed by surgery had the next longest survival, which is
likely because of downstaging of these patients prior to
surgery, presumably leading to a higher rate of surgical
tumor clearance. Shorter disease-free intervals as well as a
higher relapse rate were seen in patients who were treated
with neoadjuvant therapy, surgery, and adjuvant treat-
ment, in keeping with the fact that these patients tended
to have more advanced stage and/or residual tumor
following surgery.
DFS rates were not found to be statistically significant
between early stage and late stage cancers. This result may
be confounded by our sample size as the majority of our
patients fell into the late stage category. The survival
curves for late stage and early stage disease begin to
diverge starting at about 48 months after treatment, and it
may be that, with more prolonged follow-up, this differ-
ence may become significant.
In the late-stage group, DFS, when analyzed by treat-
ment modality showed several significant differences. The
worst survival rate was seen in the group treated with
surgery and adjuvant chemotherapy. Survival was better in
the other three treatment groups (Fig. 4), and the differ-
ences in survival between each of these three groups and
the fourth group (surgery and adjuvant chemotherapy)
were statistically significant. This is attributable to the fact
that those patients selected for only surgery had less
extensive disease and were better surgical candidates, and
that for all others neoadjuvant treatment followed by
surgery led to better local control of disease.
Evaluation of our survival rates was significantly
affected by the fact that many of our patients were lost to
follow-up after the immediate postoperative period. This is
in part because many of our patients travel long distancesto come to our institution for treatment, and find it difficult
to subsequently return for follow-up, especially if they feel
well. Although attempts were made to contact these pa-
tients, these were unsuccessful in 23.2% of patients. Men
suffered a steeper decline of survival rates compared to
women. This is possibly attributable to the higher incidence
and often more advanced stage of rectal cancers in men
compared to women in our cohort.
We report a 41.9% rate of postoperative complications.
This rate is close to that of 37.2% reported by Andreoni et al1
for rectal cancer patients and the 39% (23% early complica-
tions and 16% late complications) reported by a Polish
study.13 Our higher rate may be attributable to the fact that
we included late complications as well as early ones in our
review, whereas it is unclear whether Andreoni et al1
included late complications. Our rate is comparable to that
in the Polish study13 as the authors included both early and
late complications in their review. According to Campos
et al,14 the rates of postoperative complications vary from
20% to 42%. Improving patient follow-up might lead to better
postoperative care and minimize the rate of complications.
Overall, 39.2% of our patients received perioperative
blood transfusions. Andreoni et al1 have reported an asso-
ciation between these two factors, and postulated that this
could be because those requiring preoperative blood
transfusions tend to be in poorer general health and are
thus more likely to suffer postoperative complications,
rather than the transfusions themselves having an adverse
effect. However, we were unable to show an association
between preoperative hemoglobin level or the need for
blood transfusion and the likelihood of postoperative
complications. We also examined the association between
postoperative complications and body mass index and again
found no significant association.
The limitations of our study included the small sample
size, which may have affected the survival estimates,
similar to other studies.10 The small sample size also
limited us in evaluating survival differences between
treatment modalities. Also, we did not compare the out-
comes of patients who underwent open procedures with
those of patients who had laparoscopic procedures. This
would have undeniably had an impact on postoperative
morbidity and is worth evaluating in a prospective study.
The large number of patients who failed to follow-up
adversely affected our analysis of 5-year survival rates.5. Conclusion
Our study proves that surgical techniques currently used at
our center are successful in achieving a curative resection
rate of 75.9%, a complete remission rate of 74.1%, and an
overall survival rates at 1 year of 98%. Neoadjuvant and
adjuvant chemotherapy significantly impact rates of remis-
sion, with relapse in almost 40% of those who were unable to
complete their planned chemotherapy and radiation regi-
mens. Efforts should be made to reduce chemotherapy and
radiation toxicities in order to allow these patients to fully
benefit from standard-of-care treatment protocols.
In conclusion, appropriate surgery with complete TME
and appropriate chemotherapy and radiation, when given as
planned, ensure optimal survival in rectal cancer patients.
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